PTSD Treatment Clears FDA with 68% Remission Rate — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Wave Neuroscience received FDA clearance for its personalized brain stimulation system, MeRT, following a clinical trial that reported a 68% remission rate in PTSD patients
- Texas A&M Health Institute of Biosciences and Technology researchers collaborated with Wave Neuroscience on the trial, which showed a 52% average reduction in PTSD symptoms across participants
- MeRT uses EEG brain mapping and AI-driven transcranial magnetic stimulation tailored to individual brain activity, differing from standard TMS protocols that use one-size-fits-all approaches
- Erik Won, Wave Neuroscience’s chief medical officer, stated the treatment’s 68% remission rate represents a 'quantum change' compared to medication studies that showed at most 10.9% remission
- Dr. Kenneth S. Ramos of Texas A&M emphasized that biological differences between individuals justify precision treatment, comparing conventional TMS to covering a leaky roof with a tarp and MeRT to fixing the damaged shingles
- Dr. Rick Silva noted the FDA clearance came in just over two years—far faster than the typical 10-year medical device timeline—after the project began during the pandemic and earned Breakthrough Device designation in 2024
Why it matters: For the 13 million Americans affected by PTSD, this FDA-cleared non-drug treatment offers a viable alternative to SSRIs and intensive psychotherapy, with remission rates more than six times higher than prior medication benchmarks. The accelerated approval also signals growing regulatory openness to AI-guided neuromodulation for mental health.
Ask SkimNews
.jpg)
